ClinicalTrials.gg
RecruitingNCT06502743PENELOPEUpdated Nov 16, 2026

First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

A Phase 2 interventional study of Nesuparib and Pembrolizumab in Endometrial Cancer, Recurrent Endometrial Carcinoma and Endometrial Carcinoma, sponsored by Yonsei University. Recruiting at 8 sites in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Yonsei University · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 16, 2026Eligibility revisedStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Endometrial Neoplasms with a site in Korea, Republic of — 34 open to participants now, 59 under way, 17 of them phase 3. Endometrial Neoplasms · Korea, Republic of.

Planned enrollment
59th of 76
92 · median 287
Started
2024
with 7 others
Phase 2
19 of 85
7 open now
Primary completion
2027-12
later than 35 of 58 live
Registered
65th of 85
by date
Lead sponsor
4 of 85
Yonsei University

Among the 85 studies in Endometrial Neoplasms with a site in Korea, Republic of, this one is the 59th largest by planned enrollment of the 76 interventional ones that give a count, is one of 8 that started in 2024, is one of 19 in phase 2, reaches primary completion later than 35 of the 58 other live ones, and was the 65th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

34 of the 85 studies in Endometrial Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 19 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Endometrial Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this study is listed below.

Part A (Safety Run-in Phase) : To determine feasibility of pembrolizumab and nesuparib combination as maintenance therapy in patients with MMR-proficient advanced and recurrent endometrial cancer. Feasibility is defined as a dose-limiting toxicity (DLT) rate less than or equal to 33%.

Part B (Randomization Phase)

: To evaluate the efficacy of pembrolizumab and nesuparib combination/ pembrolizumab monotherapy as maintenance therapy in patients with MMR-proficient advanced stage and recurrent endometrial cancer. Efficacy will be assessed by investigator assessed progression free survival (PFS) as assessed by RECIST 1.1.

Read the detailed description

Part A(Safety Run-in Phase) - Pembrolizumab+ paclitaxel+ carboplatin followed by pembrolizumab combination with nesuparib

Part B(Randomization Phase)

- Pembrolizumab+ p aclitaxel+ Carboplatin followed by Pembrolizumab combination with Nesuparib vs Pembrolizumab+ Paclitaxel+ Carboplatin followed by Pembrolizumab monotherapy

03

Conditions studied

  • Endometrial Cancer
  • Recurrent Endometrial Carcinoma
  • Endometrial Carcinoma
  • Gynecologycal Cancer
  • Endometrial Neoplasms

Keywords

  • Nesuparib
  • pMMR
  • MMR-proficient
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

[Inclusion Criteria]

  1. Patient must be female ≥ 19 years of age
  2. Histologic confirmation of the original primary tumor is required. Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma not otherwise specified (N.O.S.).
  3. Measurable stage III, measurable stage IVA, stage IVB-IVC (with or without ) or recurrent (with or without measurable disease) endometrial cancer(based on the 2023 FIGO classification).
  4. MMR proficient confirmed by institutional (local) MMR IHC testing using a 4-marker panel(MSH2, MSH6, PMS2, MLH1).
  5. Patient must provide the institutional (local) P53 IHC result.
  6. Prior Therapy;

    • Naïve to systemic anti-cancer treatment. For patients with recurrent disease only, prior systemic anti-cancer treatment is allowed only if provided chemotherapy was completed ≥ 12 months prior to randomization.

      a.Note : For Part A(Safety lead in phase), patient who used Paclitaxel, Carboplatin and Pembrolizumab for first line systemic therapy can participate if they meet all of the following conditions. Patient must have had 6 cycles of chemotherapy; patient must have physician assessed stable disease (SD), partial response (PR), or complete response (CR) after 6 cycles of therapy and patient must be enrolled within 9 weeks of their last dose of chemotherapy (last dose is the day of the last infusion)

    • Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy. All radiation therapy must be completed at least 4 weeks prior to randomization.
    • Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to randomization.
  7. available or a fresh biopsy must be obtained prior to randomization.
  8. (ECOG) performance status 0, 1 or 2
  9. Have adequate organ function as defined in the following table (Table 2). Specimens must be collected within 7days prior to the start of study intervention.

1) Hematological Function:

  • (ANC) ≥1,500/µL without growth factor support within 2 weeks of screening.
  • count ≥100,000/µL without transfusion within 2 weeks of screening.
  • ≥10.0 g/dL without transfusion within 2 weeks of screening. 2) Renal Function:
  • Serum creatinine ≤1.5 × (ULN), OR measured or calculated (CrCl) ≥30 mL/min for participants with creatinine levels >1.5 × institutional ULN. (GFR) may be used instead of creatinine or CrCl. Creatinine clearance should be calculated according to institutional standards.

    3) Hepatic Function:

  • Total ≤1.5 × ULN, OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN.
  • (AST) and alanine aminotransferase (ALT) ≤3 × ULN, or ≤5 × ULN for participants with liver .

    4) Coagulation Function:

  • (INR) or prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless the participant is receiving anticoagulant therapy, provided that PT or aPTT is within the therapeutic range of the intended anticoagulant use.

    5) Thyroid Function:

  • Thyroid-stimulating hormone (TSH) within normal limits (WNL). TSH below the ULN is allowed in euthyroid patients receiving thyroid replacement therapy. Participants with abnormal TSH are eligible if free T4 is normal and the participant is clinically euthyroid.

    10.Patient has voluntarily agreed to participate by giving written /assent for the trial.

    11.Women of (WOCBP) must agree to use adequate (hormonal method or abstinence, contraceptive procedure (IUD, Mirena, etc.)) from up to 14 days prior to randomization (for oral contraceptives), during treatment, and for 6 months after the last dose of Paclitaxel + Carboplatin, for 4 months after the last dose of Pembrolizumab, for 3 months after the last dose of Nesuparib, whichever occurs last.

    12.Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:

  • (defined as at least 12 months with no menses without an alternative medical cause; in women \<45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
  • Have a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to randomization; OR Have a congenital or acquired condition that prevents childbearing.

[Exclusion Criteria]

Participants are excluded from the study if any of the following criteria apply:

  1. Patient has undergone prior treatment with a known PARP inhibitor.
  2. Patient has a known to nesuparib, pembrolizumab or combination cytotoxic chemotherapy components or .
  3. MMR deficiency confirmed by institutional MMR IHC testing.
  4. Patient has received prior treatment with immune-oncology agents as part of anti-cancer therapies.
  5. Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an agent and received cancer-directed study therapy within 4 weeks prior to randomization.
  6. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with treated may be eligible if follow-up brain imaging after CNS directed therapy shows no evidence of progression, and they have been off for at least 4 weeks prior to randomization and remain clinically stable.
  7. Patient has a known additional that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.
  8. Patient has received a or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
  9. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of therapy within 7 days prior to randomization.

    • Patients who have received steroids as CT scan contrast premedication may be enrolled.
    • The use of inhaled or topical corticosteroids is allowed.
    • The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
    • The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.
  10. Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
  11. Patient with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, noninfectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  12. Patient has a known history of (HIV) (HIV 1/2 antibodies)
  13. History of (defined as HBsAg reactive) or known active virus (defined as detectable HCV RNA [qualitative]) infection. Note: Testing for Hepatitis B or C is not required unless mandated by local health authority.
  14. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  15. Patient has known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  16. Patients with systemic disease such as Systemic Lupus Erythematosus.
  17. Has not adequately recovered from major surgery or has ongoing surgical complications.
  18. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  19. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  20. Is pregnant or breastfeeding or expecting to be pregnant or conceive children within the projected duration of the study, starting with the screening visit through 6 months after the last dose of Paclitaxel + Carboplatin, 4 months after the last dose of Pembrolizumab, 3 months after the last dose of Nesuparib, whichever occurs last.
  21. Has had an allogenic tissue/solid organ transplant.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Part B - Pembrolizumab monotherapy

    Chemotherapy Treatment Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day 1 + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks Maintenance Treatment Pembrolizumab 400 mg IV Day 1 x up to 14 cycles (o ne cycle = 6 weeks ) Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + maintenance Treatment ) = 20

    Drug: Pembrolizumab

  • Experimental
    Part B - Pembrolizumab and nesuparib combination therapy

    Combination therapy Chemotherapy Treatment Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks) Maintenance Treatment Pembrolizumab 400 mg IV Day 1 + Nesuparib 150mg or 100mg QD PO x up to 14 cycles (o ne cycle = 6 weeks ) Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + maintenance Treatment ) = 20

    Drug: Nesuparib · Drug: Pembrolizumab

  • Experimental
    Part A - Safety Run-in Phase

    Chemotherapy Treatment: Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day 1 + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks) Maintenance Treatment: Pembrolizumab 400 mg IV Day 1 + Nesuparib 150mg or 100mg QD PO x up to 14 cycles (one cycle = 6 weeks) Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + Maintenance Treatment) = 20

    Drug: Nesuparib · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities

    In Part A, To evaluate dose-limiting toxicities(DLTs) of combination maintenance treatment with pembrolizumab and nesuparib during the 21 days from first nesuparib and pembrolizumab administration, and to establish a recommended Phase 2 dose(RP2D) and dosing schedule.

    Time frame: Assessed during 21days from day 1 of first combination maintenance treatment cycle (i.e., 21 days of Cycle 8 from day 1)

  2. Overall distribution of progression-free survival

    The time from randomization to the time when Progressive disease(PD) is first confirmed after administration of the first investigational drug (Pembrolizumab) or until death without disease progression.

    Time frame: Approximately 11.01 months

Secondary outcomes

  1. 3, 6, 9 12-month Progression-free rate(PFS rate)

    the proportion of patients who are alive and without disease progression after administering the investigational product

    Time frame: 3month, 6month, 9month, 12month after the study enrollment

  2. Median Progression-free time(Median PFS time)

    the proportion of patients who are alive and without disease progression after administering the investigational product

    Time frame: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

  3. Overall response rate(ORR)

    the proportion of patients achieving complete remission(CR) or partial response(PR) as assessed by the Investigator per RECIST(v1.1) in patients who enter the study with measurable disease.

    Time frame: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

  4. Duration control rate(DCR)

    the proportion of subjects who have achieved a best overall response of complete remission(CR), partial response(PR), or stable disesae(SD) per RECIST v.1.1 based on Investigator assessment.

    Time frame: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

  5. Duration of response(DOR)

    DOR applies only to subjects whose BOR was CR or PR in patients who enter the study with measurable disease according to RECIST v.1.1 using the Investigator's tumor assessment. The start date is the date of first documented response (CR or PR), and the end date is the date defined as first documented PD or death due to any cause. If a subject had not had an event, duration will be censored at the date of last adequate tumor assessment.

    Time frame: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

  6. Overall survival(OS)

    the time from the first date of investigational product administration to the date of death for any reason.

    Time frame: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

  7. Progression free survival 2(PFS2)

    the time from the first date of administration of the investigational product to the earlier of disease progression or death in the subsequent anticancer therapy.

    Time frame: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

07

Study locations

8 of 8 sites recruiting
08

References and documents

Publications

  • Kim SI, Cho HW, Choi CH, Park JY, Lee JB, Kim JW, Kim BG, Kim J, Lee JY. Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE). J Gynecol Oncol. 2026 Jan;37(1):e50. doi: 10.3802/jgo.2026.37.e50. Epub 2025 Dec 22. PubMed 41514313 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.

Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's planned 39 months is below that.

Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2024
First posted
Jul 16, 2024
StartActual
Sep 12, 2024
Primary completionEst.
Dec 27, 2027
CompletionEst.
Dec 27, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed
Show 3 added (3 South Korea)
  • Seoul National University Bundang Hospital · Seongnam-si, South Korea
  • National Cancer Center · Goyang-si, South Korea
  • The Catholic University of Korea, Seoul St. Mary's Hospital · Seoul, South Korea
Show 1 removed
  • National Cancer Center · Kyeonggi-do, Korea, Republic of
Nov 16, 2026
Eligibility
1 inclusion criterion removed; 14 criteria edited, 9 added
What changed in the criteria
  • Added[Inclusion Criteria]
  • EditedMeasurable stage III, measurable stage IVA, stage IVB-IVC (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer(based on the 2023 FIGO classification).
  • EditedMMR proficient confirmed by institutional (local) MMR IHC testing using a 4-marker panel(MSH2, MSH6, PMS2, MLH1).
  • Editeda.Note : For Part A(Safety lead in phase), patient who used Paclitaxel, Carboplatin and Pembrolizumab for first line systemic therapy can participate if they meet all of the following conditions. Patient must have had 6 cycles of chemotherapy; patient must have physician assessed stable disease (SD), partial response (PR), or complete response (CR) after 6 cycles of therapy and patient must be enrolled within 9 weeks of their last dose of chemotherapy (last dose is the day of the last infusion)
  • EditedHave adequate organ function as defined in the following table (Table 2). Specimens must be collected within 7days prior to the start of study intervention.
  • Added1) Hematological Function:
  • EditedHematology Absolute neutrophil count (ANC) ≥1,500/μLµL without growth factor support within 2 weeks beforeof screening test.
  • EditedPlatelet count ≥100,000/μLµL without transfusion within 2 weeks prior toof screening test.
  • EditedHemoglobin ≥10.0 g/dL without transfusion within 2 weeks prior toof screening test.. 2) Renal Function:
  • AddedSerum creatinine ≤1.5 × upper limit of normal (ULN), OR measured or calculated creatinine clearance (CrCl) ≥30 mL/min for participants with creatinine levels >1.5 × institutional ULN. Glomerular filtration rate (GFR) may be used instead of creatinine or CrCl. Creatinine clearance should be calculated according to institutional standards.
  • Added3) Hepatic Function:
  • Editedliver function Total bilirubin ≤1.5 × ULN or, OR direct bilirubin ≤ULN for subjects whoseparticipants with total bilirubin exceeds levels >1.5 times the normal value× ULN.
  • EditedASTAspartate aminotransferase (SGOTAST) and ALTalanine aminotransferase (SGPTALT) ≤3 × ULN (, or ≤5 × ULN in subjectsfor participants with liver metastases).
  • Added4) Coagulation Function:
  • EditedCoagulation International normalized ratio (INR) or prothrombin time (PT) Activated, and activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless the participant is receiving anticoagulant therapy, provided that PT or aPTT is within the therapeutic range of the intended anticoagulant use.
  • Added5) Thyroid Function:
  • EditedThyroid function Thyroid -stimulating hormone (TSH) within normal limits (WNL); In. TSH below the ULN is allowed in euthyroid subjectspatients receiving thyroid replacement therapy, TSH < ULN; If an. Participants with abnormal TSH result is shown,are eligible if free T4 is normal, and glandular function (euthyroid)the participant is clinically normal, registration is possibleeuthyroid.
  • Edited10.Patient has voluntarily agreed to participate by giving written informed consent/assent for the trial.
  • Edited11.Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal method or abstinence, contraceptive procedure (IUD, Mirena, etc.)) from up to 14 days prior to randomization (for oral contraceptives), during treatment, and for 6 months after the last dose of Paclitaxel + Carboplatin, for 4 months after the last dose of Pembrolizumab, for 3 months after the last dose of Nesuparib, whichever occurs last.
  • Edited12.Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:
  • Added[Exclusion Criteria]
  • AddedParticipants are excluded from the study if any of the following criteria apply:
  • AddedPatient has received prior treatment with immune-oncology agents as part of anti-cancer therapies.
Inclusion criteria
  • RemovedKidney function Creatinine or measured or calculated creatinine clearance (GFR may also be used in place of creatinine or CrCl a) ≤1.5 × ULN or ≥30 mL/min for subjects with creatinine levels >1.5 × institutional ULN.
Nov 16, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41514313 ↗
Nov 16, 2026
Contact
Study contact's phone or email changed: •••2237→•••0430; J•••@yuhs.ac→i•••@yuhs.ac. See the current contact
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41514313 ↗
    3 sites added, 1 site removed
    Show 3 added (3 South Korea)
    • Seoul National University Bundang Hospital · Seongnam-si, South Korea
    • National Cancer Center · Goyang-si, South Korea
    • The Catholic University of Korea, Seoul St. Mary's Hospital · Seoul, South Korea
    Show 1 removed
    • National Cancer Center · Kyeonggi-do, Korea, Republic of
    Eligibility 1 inclusion criterion removed; 14 criteria edited, 9 added
    What changed in the criteria
    • Added[Inclusion Criteria]
    • EditedMeasurable stage III, measurable stage IVA, stage IVB-IVC (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer(based on the 2023 FIGO classification).
    • EditedMMR proficient confirmed by institutional (local) MMR IHC testing using a 4-marker panel(MSH2, MSH6, PMS2, MLH1).
    • Editeda.Note : For Part A(Safety lead in phase), patient who used Paclitaxel, Carboplatin and Pembrolizumab for first line systemic therapy can participate if they meet all of the following conditions. Patient must have had 6 cycles of chemotherapy; patient must have physician assessed stable disease (SD), partial response (PR), or complete response (CR) after 6 cycles of therapy and patient must be enrolled within 9 weeks of their last dose of chemotherapy (last dose is the day of the last infusion)
    • EditedHave adequate organ function as defined in the following table (Table 2). Specimens must be collected within 7days prior to the start of study intervention.
    • Added1) Hematological Function:
    • EditedHematology Absolute neutrophil count (ANC) ≥1,500/μLµL without growth factor support within 2 weeks beforeof screening test.
    • EditedPlatelet count ≥100,000/μLµL without transfusion within 2 weeks prior toof screening test.
    • EditedHemoglobin ≥10.0 g/dL without transfusion within 2 weeks prior toof screening test.. 2) Renal Function:
    • AddedSerum creatinine ≤1.5 × upper limit of normal (ULN), OR measured or calculated creatinine clearance (CrCl) ≥30 mL/min for participants with creatinine levels >1.5 × institutional ULN. Glomerular filtration rate (GFR) may be used instead of creatinine or CrCl. Creatinine clearance should be calculated according to institutional standards.
    • Added3) Hepatic Function:
    • Editedliver function Total bilirubin ≤1.5 × ULN or, OR direct bilirubin ≤ULN for subjects whoseparticipants with total bilirubin exceeds levels >1.5 times the normal value× ULN.
    • EditedASTAspartate aminotransferase (SGOTAST) and ALTalanine aminotransferase (SGPTALT) ≤3 × ULN (, or ≤5 × ULN in subjectsfor participants with liver metastases).
    • Added4) Coagulation Function:
    • EditedCoagulation International normalized ratio (INR) or prothrombin time (PT) Activated, and activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless the participant is receiving anticoagulant therapy, provided that PT or aPTT is within the therapeutic range of the intended anticoagulant use.
    • Added5) Thyroid Function:
    • EditedThyroid function Thyroid -stimulating hormone (TSH) within normal limits (WNL); In. TSH below the ULN is allowed in euthyroid subjectspatients receiving thyroid replacement therapy, TSH < ULN; If an. Participants with abnormal TSH result is shown,are eligible if free T4 is normal, and glandular function (euthyroid)the participant is clinically normal, registration is possibleeuthyroid.
    • Edited10.Patient has voluntarily agreed to participate by giving written informed consent/assent for the trial.
    • Edited11.Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal method or abstinence, contraceptive procedure (IUD, Mirena, etc.)) from up to 14 days prior to randomization (for oral contraceptives), during treatment, and for 6 months after the last dose of Paclitaxel + Carboplatin, for 4 months after the last dose of Pembrolizumab, for 3 months after the last dose of Nesuparib, whichever occurs last.
    • Edited12.Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:
    • Added[Exclusion Criteria]
    • AddedParticipants are excluded from the study if any of the following criteria apply:
    • AddedPatient has received prior treatment with immune-oncology agents as part of anti-cancer therapies.
    Inclusion criteria
    • RemovedKidney function Creatinine or measured or calculated creatinine clearance (GFR may also be used in place of creatinine or CrCl a) ≤1.5 × ULN or ≥30 mL/min for subjects with creatinine levels >1.5 × institutional ULN.
    Contact Study contact's phone or email changed: •••2237→•••0430; J•••@yuhs.ac→i•••@yuhs.ac. See the current contact
    + 4 other changes: verification date, date precision, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06502743
Lead sponsor
Yonsei University
Responsible party
JUNGYUN LEE (Professor, Yonsei University) — Principal investigator
First posted
Jul 16, 2024
Start date
Sep 12, 2024
Primary completion
Dec 27, 2027 (estimated)
Completion
Dec 27, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

JUNGYUN LEE, Ph.D
Contact
irb@yuhs.ac
+82-2-2228-0430

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nesuparib

Start the discussion